Approved for:

U.S. Patient and Trademak Offic

Under the Papervork Reduction Act of 1995, no persons are required to respond to a collection of information unline

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10691806			
Filing Date			2003-10-21			
First Named Inventor Barto		Barto	on et al.			
	Art Unit		3653			
	Examiner Name	Unkr	iown			
	Attorney Docket Number		112703-294			

		Remove				
Examiner   Cite   Patent Number   Kind   Code1		Issue Date Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	4645036		1987-02-24	Nestler	
2 6193154 2001-02-27 Philips ot al.		Philips ot al.				
	3 5992570 1999-11-30 Watter et al. 4 6921362 2009-92-91 Maggand et al.		Walter et al.			
			Maggard et al.			
5		6116505		2000-09-12	Withrow	
	6	6356794		2002-03-12	Penn et al.	
	7	6598790		2003-07-29	Horst	
If you wish	to ac	dd additional U.S. Pate			lease click the Add button.	Add

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10691806
Filing Date		2003-10-21
First Named Inventor Barto		n et al.
Art Unit		3653
Examiner Name Unkn		own
Attorney Docket Number		112703-294

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ation	Name of Patentee or Applicant of cited Document Pages, Columns, Lin Relevant Passages Figures Appear		ges or Relev			
	1	20020145037		2002-10-10		Goodwin					
	2	20050128087		2005-06-16		Claessens et al.					
If you wis	h to a	dd additional U.S. Publ	ished Ap	plication	citatio	n information p	please click the Ad	d butto	n. Add		
				FOREIG	GN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup> Publication Date Name of Patentee or Applicant of cited Document Passages or Figures Appe		levant or Relevant	т			
	1										
If you wisl	h to a	dd additional Foreign F	atent Do	cument	citation	information pl	lease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (took, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), To publisher, city and/or country where published.					Тŝ					
	1 International Search Report for International Patent Application No. PCT/US05/28545 that corresponds to the present application and of which the references cited above was cited therein.										
If you wis	h to a	dd additional non-pater	nt literatu	ire docui	ment cit	ation informat	ion please click the	Add b	utton A	dd	
				EX	AMINE	R SIGNATUR	E				
Eveniner	C:	4					Data Conside				_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10691806	
	Filing Date		2003-10-21	
	First Named Inventor Barto		n et al.	
	Art Unit		3653	
	Examiner Name	Unkn	own	
	Attorney Docket Numb	er	112703-294	

See for Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. \* Exister office in all research on documents, by the loss before code (WPO) Standard 51.3. \* \*Per Legislance plant of comments, the indusion to the your of the region of the Engeneer patient control the search rection of the patient document. \*
\*Indicate of coursent by the appropriate symbols as indicated on the document under WPO Standard 51.56 if possible. \*\*
\*Indicate of coursent by the appropriate symbols as indicated on the document under WPO Standard 51.56 if possible. \*
\*Indicate of course the propriate symbols as an experience of the patient document of the patient document. \*
\*Indicate of course the patient document of the patient document of the patient document. \*
\*Indicate of the patient document of the patient document. \*
\*Indicate of the patient document. \*
\*I

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10691806	
Filing Date			2003-10-21	
First Named Inventor Barton		Barto	n et al.	
	Art Unit			3653
	Examiner Name	Unkn	own	
	Attorney Docket Number		112703-294	

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
7	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(eV1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 178(b) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(b) (2)

٦.	See attached certification	etatement

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Matthew T. Ridsdale/	Date (YYYY-MM-DD)	2006-04-20
Name/Print	Matthew T. Didertale	Registration Number	56832

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, and Comparined of Commence, P. 0. Bot 1450, Alexandria, V.32.211-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, V.32.231-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.